Amarin Corp Plc (AMRN)

[Sam81]

REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180912:nGNXCxTPL


BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2018 (GLOBE NEWSWIRE) --
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced that the primary results of Amarin’s
cardiovascular outcomes study of Vascepa, the REDUCE-IT study, have been
accepted for presentation at the 2018 Scientific Sessions of American Heart
Association (AHA) on November 10, 2018 in Chicago, Illinois.  The
presentation, classified as late-breaking clinical trial results, is scheduled
to commence at 2:16 pm Central Time and listed as Main Event 1 for that
timeframe.  A link to this notice is provided at:
http://www.abstractsonline.com/pp8/#!/4682/presentation/59402.

This acceptance as a presentation of late-breaking clinical trial results is
based on the ability of REDUCE-IT to address a critical question in
cardiovascular prevention.  The AHA has reviewed the design of the REDUCE-IT
study, however, they have not yet seen the results of the study.  As Amarin
has guided in the past, topline results of this study are anticipated to be
made public prior to the end of this month, September 2018. The AHA has not
been provided any advanced access to the results of this study.